ciglitazone has been researched along with Hypertrophy, Left Ventricular in 2 studies
ciglitazone: structure given in second source; PPAR agonist used for type II diabetes
ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.
Hypertrophy, Left Ventricular: Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality.
| Excerpt | Relevance | Reference |
|---|---|---|
| " To test the hypothesis that PPARgamma decreased LVH and cardiac fibrosis in chronic pressure overload, in part, by increasing SOD, eNOS and elastin and decreasing NOX4, MMP and collagen synthesis and degradation, chronic pressure overload analogous to systemic hypertension was created in C57BL/6J mice by occluding the abdominal aorta above the kidneys (aortic stenosis-AS)." | 7.74 | Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. ( Henderson, BC; Kartha, GK; Moshal, KS; Ovechkin, A; Reynolds, C; Rodriguez, WE; Sen, U; Tyagi, N; Tyagi, SC, 2007) |
| " To test the hypothesis that PPARgamma decreased LVH and cardiac fibrosis in chronic pressure overload, in part, by increasing SOD, eNOS and elastin and decreasing NOX4, MMP and collagen synthesis and degradation, chronic pressure overload analogous to systemic hypertension was created in C57BL/6J mice by occluding the abdominal aorta above the kidneys (aortic stenosis-AS)." | 3.74 | Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone. ( Henderson, BC; Kartha, GK; Moshal, KS; Ovechkin, A; Reynolds, C; Rodriguez, WE; Sen, U; Tyagi, N; Tyagi, SC, 2007) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Smiley, LM | 1 |
| Camp, TM | 1 |
| Lucchesi, PA | 1 |
| Tyagi, SC | 2 |
| Henderson, BC | 1 |
| Sen, U | 1 |
| Reynolds, C | 1 |
| Moshal, KS | 1 |
| Ovechkin, A | 1 |
| Tyagi, N | 1 |
| Kartha, GK | 1 |
| Rodriguez, WE | 1 |
2 other studies available for ciglitazone and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Peroxisome proliferator ameliorates endocardial endothelial and muscarinic dysfunction in spontaneously hypertensive rats.
Topics: Acetylcholine; Animals; Cholinergic Agents; Endothelium; Fibrosis; Heart; Hypertension; Hypertrophy, | 2004 |
Reversal of systemic hypertension-associated cardiac remodeling in chronic pressure overload myocardium by ciglitazone.
Topics: Animals; Collagen; Elastin; Fibrosis; Heart; Hypertension; Hypertrophy, Left Ventricular; Hypoglycem | 2007 |